Bharat Biotech announced the launch of India's first indigenously developed cell culture H1N1 swine flu vaccine under the brand name 'HNVAC™'. HNVAC™ is the only developing world flu vaccine to be manufactured in cell culture, a highly sterile and controlled manufacturing process, instead of...
BIO today announced the preliminary set of speakers who will be featured on the Therapeutic Workshops during the 9th Annual BIO Investor Forum - a national meeting focused on investment trends and opportunities in the life-sciences with a focus on public and venture-stage growth companies...
Minneapolis Star Tribune, on the Biotechnology Industry Organization's convention in Chicago: "The biotechnology industry, hurt by the recession, is looking for inspiration from Charles Darwin. Leading executives say unless biotech companies adapt to a less-robust economy and changing industry...
Bharat Biotech today announced that it has commenced Phase I clinical evaluation of HN-VAC, its cell culture based H1N1 vaccine candidate. Bharat Biotech received the nod from Drugs Controller General of India (DCGI) to conduct the Phase I clinical trials. This vaccine under development will...
PCI Biotech AS ( PCIB.OL) (OSE:PCIB) reported today that it has completed the successful treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. To date seven patients have...
Bharat Biotech today announced that it has commenced Phase I clinical evaluation of HN-VAC, its cell culture based H1N1 vaccine candidate. Bharat Biotech received the nod from Drugs Controller General of India (DCGI) to conduct the Phase I clinical trials. This vaccine under development will...
PCI Biotech AS ( PCIB.OL) (OSE:PCIB) reported today that it has completed the successful treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. To date seven patients have...
Moffitt Cancer Center will host its fourth-annual Business of Biotech: Vision + Drive = Innovation conference from 8 a.m. to 1 p.m. Feb. 1 in the Vincent A. Stabile Research Building, 12902 Magnolia Drive. "We are delighted Dr. Garry Nolan, tenured professor at the Stanford University School...
Facet Biotech Corporation (NASDAQ: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented at the...